Clinical Trial

Multiple Sclerosis Implementation Network (Registry)

Recruiting
View on ClinicalTrials.gov →
Summary
The Multiple Sclerosis Implementation Network (MSIN) is a collaboration between the Multiple Sclerosis Association of America (MSAA), The University of Texas Health Science Center at Houston (UTHealth Houston), Dell Medical School at The University of Texas at Austin, and Novartis Pharmaceuticals Corporation. The goal of MSIN is to improve Multiple Sclerosis (MS) care, patient health, and quality of life through the development and support of implementation research and clinical practice collaboration. MSIN brings together healthcare teams, people with MS, and research leaders in MS and implementation science (IS) to learn, share, test, implement, and disseminate innovations that improve MS care, patient health, and quality of life. This ClinicalTrials.gov record pertains to the MSIN Patient Registry, which is a comprehensive database that integrates participants' electronic health records from various providers.
Trial Details
NCT Number NCT07415824
Lead Sponsor The University of Texas Health Science Center, Houston
Collaborators: Novartis, Multiple Sclerosis Association of America, The University of Texas at Austin
Conditions Multiple Sclerosis
Enrollment 2,000 participants
Start Date 2025-04-28
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-17